Global- and Renal-Specific Sympathoinhibition in Aldosterone Hypertension

Hypertension

Volumn 65, Issue 6, 2015, Pages 1223-1230

  Lohmeier, Thomas E ^a   Liu, Boshen ^a   Hildebrandt, Drew A ^a   Cates, Adam W ^b   Georgakopoulos, Dimitrios ^b   Irwin, Eric D ^c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b CVRX INC   (United States)

^c NORTH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

aldosterone; arterial pressure; baroreflex; sympathetic nervous system; vasopressin, kidney

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; NORADRENALIN; RENIN;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE HYPERTENSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; CARDIAC PATIENT; CAROTID SINUS PRESSORECEPTOR REFLEX; CONTROLLED STUDY; ELECTROLYTE URINE LEVEL; EXPERIMENTAL DOG; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FUNCTION; KIDNEY NERVE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PLASMA OSMOLALITY; PRIORITY JOURNAL; RESISTANT HYPERTENSION; SYMPATHETIC TONE; VASOPRESSIN RELEASE; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DISEASE MODEL; DOG; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSORECEPTOR REFLEX; PROCEDURES; RANDOMIZATION; REFERENCE VALUE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SYMPATHECTOMY;

ALDOSTERONE; ANALYSIS OF VARIANCE; ANIMALS; BAROREFLEX; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERTENSION; LINEAR MODELS; MALE; NOREPINEPHRINE; RANDOM ALLOCATION; REFERENCE VALUES; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SYMPATHECTOMY;

EID: 84937597645     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05155     Document Type: Article

References (40)

1. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-773. doi: 10.1016/j.jacc.2011.06.008.
2. Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6:152-158. doi: 10.1016/j. jash.2012.01.003.
3. Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, Cates AW, Lovett EG, Haller H. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6:270-276. doi: 10.1016/j.jash.2012.04.004.
4. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension. Durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-917.
5. Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35:1752-1759. doi: 10.1093/eurheartj/ehu209.
6. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-e526. doi: 10.1161/CIRCULATIONAHA.108.189141.
7. Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28:318-325. doi: 10.1016/j. cjca.2012.03.010.
8. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159-1164. doi: 10.1001/archinte.168.11.1159.
9. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, Inusah S, Gupta H, Lloyd SG, Oparil S, Husain A, DellItalia LJ, Calhoun DA. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55:1137-1142. doi: 10.1161/HYPERTENSIONAHA.109.141531.
10. Persu A, Jin Y, Baelen M, et al; European Network Coordinating research on REnal Denervation Consortium. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension. 2014;63:1319-1325. doi: 10.1161/HYPERTENSIONAHA.114.03194.
11. Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839-845. doi: 10.1161/01. HYP.0000259805.18468.8c.
12. de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147-152. doi: 10.1161/HYPERTENSIONAHA.109.140988.
13. Václavík J, Sedlák R, Plachý M, Navrátil K, Plásek J, Jarkovský J, Václavík T, Husár R, Kociánová E, Táborský M. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT). A randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57:1069-1075.
14. Rosa J, Widimský P, Toušek P, et al. Randomized comparison of renal denervation versus intensified pharmacotherapy including spironolactone in true-resistant hypertension. Six month results from the Prague-15 study. Hypertension. 2015;65:407-413. doi: 10.1161/HYPERTENSIONAHA.114.04019.
15. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57:1076-1080. doi: 10.1161/HYPERTENSIONAHA.111.170308.
16. Grassi G, Seravalle G, Brambilla G, Pini C, Alimento M, Facchetti R, Spaziani D, Cuspidi C, Mancia G. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177:1020-1025. doi: 10.1016/j.ijcard.2014.09.138.
17. Lohmeier TE, Iliescu R, Liu B, Henegar JR, Maric-Bilkan C, Irwin ED. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2012;59:331-338. doi: 10.1161/HYPERTENSIONAHA.111.185074.
18. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O, Ishii M. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17(6 Pt 2):1057-1062.
19. León LA, McKinley MJ, McAllen RM, May CN. Aldosterone acts on the kidney, not the brain, to cause mineralocorticoid hypertension in sheep. J Hypertens. 2002;20:1203-1208.
20. Matsukawa T, Miyamoto T. Does infusion of ANG II increase muscle sympathetic nerve activity in patients with primary aldosteronism? Am J Physiol Regul Integr Comp Physiol. 2008;294:R1873-R1879. doi: 10.1152/ajpregu.00471.2007.
21. Geerling JC, Loewy AD. Aldosterone in the brain. Am J Physiol Renal Physiol. 2009;297:F559-F576. doi: 10.1152/ajprenal.90399.2008.
22. Kontak AC, Wang Z, Arbique D, Adams-Huet B, Auchus RJ, Nesbitt SD, Victor RG, Vongpatanasin W. Reversible sympathetic overactivity in hypertensive patients with primary aldosteronism. J Clin Endocrinol Metab. 2010;95:4756-4761. doi: 10.1210/jc.2010-0823.
23. Lohmeier TE, Hildebrandt DA, Dwyer TM, Barrett AM, Irwin ED, Rossing MA, Kieval RS. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension. 2007;49:373-379. doi: 10.1161/01.HYP.0000253507.56499.bb.
24. Thrasher TN, Keil LC. Systolic pressure predicts plasma vasopressin responses to hemorrhage and vena caval constriction in dogs. Am J Physiol Regul Integr Comp Physiol. 2000;279:R1035-R1042.
25. Stocker SD, Stricker EM, Sved AF. Arterial baroreceptors mediate the inhibitory effect of acute increases in arterial blood pressure on thirst. Am J Physiol Regul Integr Comp Physiol. 2002;282:R1718-R1729. doi: 10.1152/ajpregu.00651.2001.
26. Lohmeier TE, Dwyer TM, Hildebrandt DA, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Influence of prolonged baroreflex activation on arterial pressure in angiotensin hypertension. Hypertension. 2005;46:1194-1200. doi: 10.1161/01.HYP.0000187011.44201.2e.
27. Lohmeier TE, Irwin ED, Rossing MA, Serdar DJ, Kieval RS. Prolonged activation of the baroreflex produces sustained hypotension. Hypertension. 2004;43:306-311. doi: 10.1161/01.HYP.0000111837.73693.9b.
28. Lohmeier TE, Iliescu R, Dwyer TM, Irwin ED, Cates AW, Rossing MA. Sustained suppression of sympathetic activity and arterial pressure during chronic activation of the carotid baroreflex. Am J Physiol Heart Circ Physiol. 2010;299:H402-H409. doi: 10.1152/ajpheart.00372.2010.
29. Hall JE, Guyton AC, Farr BM. A single injection method for measuring glomerular filtration rate. Am J Physiol. 1977;232:F72-F76.
30. Lohmeier TE, Kastner PR, Smith MJ, Guyton AC. Is aldosteronism important in the maintenance of arterial blood pressure and electrolyte balance during sodium depletion? Hypertension. 1980;2:497-505.
31. Leenen FH. Actions of circulating angiotensin II and aldosterone in the brain contributing to hypertension. Am J Hypertens. 2014;27:1024-1032. doi: 10.1093/ajh/hpu066.
32. Kandlikar SS, Fink GD. Mild DOCA-salt hypertension: sympathetic system and role of renal nerves. Am J Physiol Heart Circ Physiol. 2011;300:H1781-H1787. doi: 10.1152/ajpheart.00972.2010.
33. Bravo EL, Tarazi RC, Dustan HP. Multifactorial analysis of chronic hypertension induced by electrolyte-active steroids in trained, unanesthetized dogs. Circ Res. 1977;40(5 Suppl 1):I140-I145.
34. Pirpiris M, Cox H, Esler M, Jennings GL, Whitworth JA. Mineralocorticoid induced hypertension and noradrenaline spillover in man. Clin Exp Hypertens. 1994;16:147-161.
35. Bravo EL, Tarazi RC, Dustan HP, Fouad FM. The sympathetic nervous system and hypertension in primary aldosteronism. Hypertension. 1985;7:90-96.
36. Lohmeier TE, Iliescu R. Lowering of blood pressure by chronic suppression of central sympathetic outflow: insight from prolonged baroreflex activation. J Appl Physiol (1985). 2012;113:1652-1658. doi: 10.1152/japplphysiol.00552.2012.
37. Iliescu R, Lohmeier TE. Lowering of blood pressure during chronic suppression of central sympathetic outflow: insight from computer simulations. Clin Exp Pharmacol Physiol. 2010;37:e24-e33. doi: 10.1111/j.1440-1681.2009.05291.x.
38. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension. 2015;65:257-263. doi: 10.1161/HYPERTENSIONAHA.114.04488.
39. Kandzari DE, Bhatt DL, Brar S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J. 2015;36:219-227. doi: 10.1093/eurheartj/ehu441.
40. Muxfeldt E, de Souza F, Margallo VS, Salles GF. Cardiovascular and renal complications with resistant hypertension. Curr Hypertens Rep. 2014;16:471-477.